For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website or call (605) 755-2300.
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
EAY131: Molecular Analysis for Therapy Choice (MATCH)
EAY131-F: MATCH Treatment Sub-protocol F: Crizotnib in Patients with Tumors (other than adenocarcinoma of Lung or ALCL) with ALK Translocations
EAY131-G: MATCH Treatment Sub-protocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
EAY131-H: MATCH Treatment Sub-protocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (excluding melanoma and thyroid cancer)
EAY131-R: MATCH Treatment Sub-protocol R: Phase II Study of Trametinib in Patients with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations
PURPOSE: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.
A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin As Adjuvant Therapy For Node Positive HER2 Negative Breast Cancer: The ABC Trial
|To learn more, contact:
John T. Vucurevich Cancer Care Institute
Michael Robinson, MD